Merck and Moderna to develop a personalised cancer vaccine
Drug Discovery World
OCTOBER 14, 2022
“We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalised cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, President of Moderna.
Let's personalize your content